ES2181744T3 - Hidratos de paclitaxel cristalinos. - Google Patents

Hidratos de paclitaxel cristalinos.

Info

Publication number
ES2181744T3
ES2181744T3 ES95119595T ES95119595T ES2181744T3 ES 2181744 T3 ES2181744 T3 ES 2181744T3 ES 95119595 T ES95119595 T ES 95119595T ES 95119595 T ES95119595 T ES 95119595T ES 2181744 T3 ES2181744 T3 ES 2181744T3
Authority
ES
Spain
Prior art keywords
paclitaxel
hydrapts
cristalinos
pseudopolymorph
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95119595T
Other languages
English (en)
Other versions
ES2181744T5 (es
Inventor
Robert K Perrone
Scott R Stenberg
Murray A Kaplan
Akram Saab
Shreeram Agharkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23396320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2181744(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2181744T3 publication Critical patent/ES2181744T3/es
Publication of ES2181744T5 publication Critical patent/ES2181744T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN NUEVO COMPUESTO PSEUDOPOLIMORFO DE PACLITAXEL, A UNA COMPOSICION FARMACEUTICA QUE LO CONTIENE Y A SU USO COMO AGENTE ANTITUMORAL. OTROS ASPECTOS DE LA INVENCION SE REFIEREN A LA PREPARACION DE ESTE COMPUESTO PSEUDOPOLIMORFO.
ES95119595T 1994-12-13 1995-12-12 Hidrato de paclitaxel cristalino. Expired - Lifetime ES2181744T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35512594A 1994-12-13 1994-12-13
US355125 1994-12-13

Publications (2)

Publication Number Publication Date
ES2181744T3 true ES2181744T3 (es) 2003-03-01
ES2181744T5 ES2181744T5 (es) 2008-03-01

Family

ID=23396320

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95119595T Expired - Lifetime ES2181744T5 (es) 1994-12-13 1995-12-12 Hidrato de paclitaxel cristalino.

Country Status (9)

Country Link
EP (1) EP0717041B2 (es)
JP (1) JPH08208636A (es)
AT (1) ATE221879T1 (es)
AU (1) AU699542B2 (es)
CA (1) CA2163837C (es)
DE (1) DE69527696T3 (es)
DK (1) DK0717041T3 (es)
ES (1) ES2181744T5 (es)
PT (1) PT717041E (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
FR2729666A1 (fr) * 1995-01-25 1996-07-26 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r, 3s)- benzoylamino-2-hydroxy-3-phenylpropionate de 4,10-diacetoxy- 2alpha-benzoyloxy-5beta,20-epoxy-1,7beta-dihydroxy-9-oxo- tax-11-en-13alpha-yle
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
EP2292225B9 (en) † 1997-03-31 2012-06-27 Boston Scientific Scimed Limited Dosage form comprising taxol in crystalline form
HUP9701945A3 (en) * 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
US6136989A (en) * 1998-12-30 2000-10-24 Phytogen Life Sciences, Incorporated Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material
PL203300B1 (pl) * 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
HUP0600533A2 (en) 2001-11-30 2006-11-28 Bristol Myers Squibb Co Paclitaxel solvates
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
US7919108B2 (en) 2006-03-10 2011-04-05 Cook Incorporated Taxane coatings for implantable medical devices
US7875284B2 (en) 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
WO2008005284A2 (en) * 2006-06-30 2008-01-10 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
CA2743022C (en) 2007-01-21 2012-10-09 Hemoteq Ag Methods for coating catheter balloons with a defined quantity of active agent
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
FR2926551A1 (fr) * 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
JP2012532670A (ja) 2009-07-10 2012-12-20 ボストン サイエンティフィック サイムド，インコーポレイテッド 薬剤搬送バルーンのためのナノ結晶の使用
EP2962707B1 (en) 2009-07-17 2019-07-24 Boston Scientific Scimed, Inc. Drug delivery balloons with improved crystal size and density
EP2611476B1 (en) 2010-09-02 2016-08-10 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
WO2013022458A1 (en) 2011-08-05 2013-02-14 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
US9056152B2 (en) 2011-08-25 2015-06-16 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
CN111803698B (zh) * 2014-02-14 2022-05-27 波士顿科学国际有限公司 具有治疗剂释放的快速降解栓塞颗粒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) † 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) † 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5380916A (en) † 1990-11-02 1995-01-10 University Of Florida Method for the isolation and purification of taxane derivatives
TW467896B (en) † 1993-03-19 2001-12-11 Bristol Myers Squibb Co Novel β-lactams, methods for the preparation of taxanes and sidechain-bearing taxanes

Also Published As

Publication number Publication date
DE69527696D1 (de) 2002-09-12
EP0717041A1 (en) 1996-06-19
PT717041E (pt) 2002-11-29
DE69527696T2 (de) 2003-04-03
CA2163837C (en) 1999-07-20
AU699542B2 (en) 1998-12-03
AU4035595A (en) 1996-06-20
ATE221879T1 (de) 2002-08-15
ES2181744T5 (es) 2008-03-01
CA2163837A1 (en) 1996-06-14
JPH08208636A (ja) 1996-08-13
DE69527696T3 (de) 2008-04-03
EP0717041B1 (en) 2002-08-07
DK0717041T3 (da) 2002-11-25
EP0717041B2 (en) 2007-08-15

Similar Documents

Publication Publication Date Title
ES2181744T3 (es) Hidratos de paclitaxel cristalinos.
PT960107E (pt) Compostos de paclitaxel 6-tio-substituidos
HU9402342D0 (en) Phosphono-oxymethyl-ethers of taxane derivatives
ES2147739T3 (es) Fosfonooximetil-eteres de derivados de taxano.
ATE231872T1 (de) Thiazolopyrimidinderivate
DE69709407D1 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
MX9601994A (es) Profarmacos de derivados de paclitaxel.
CA2152771A1 (en) 7-o-ethers of taxane derivatives
DE60029084D1 (de) Neue depsipeptid-verbindung
PT1011329E (pt) Paclitaxeis de 7-metiltio-oxometilo e 7-metiltiodioxometilo
FI965166A (fi) Uusia kasvaimen- ja leukemianvastaisia aineita, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia